Progression of diabetic nephropathy: Role of plasma homocysteine and plasminogen activator inhibitor-1

American Journal of Kidney Diseases

Volumn 38, Issue 6, 2001, Pages 1376-1380

  Hovind, Peter ^a,b,c   Tarnow, Lise ^a,b,c   Rossing, Peter ^a,b,c   Teerlink, Tom ^a,b,c   Stehouwer, Coen D A ^a,b,c   Emeis, Jef J ^a,b,c   Parving, Hans Henrik ^a,b,c  

^a STENO DIABETES CENTER   (Denmark)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c TNO   (Netherlands)

Author keywords

Diabetic nephropathy; Homocysteine; Plasminogen activator inhibitor 1; Type 1 diabetes

Indexed keywords

ALBUMIN; HEMOGLOBIN A1C; HOMOCYSTEINE; PLASMINOGEN ACTIVATOR INHIBITOR 1;

ADULT; BLOOD LEVEL; CONFERENCE PAPER; DIABETIC NEPHROPATHY; DISEASE COURSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GLOMERULUS FILTRATION RATE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MAJOR CLINICAL STUDY; MALE; PREDICTION; RISK FACTOR;

EID: 0035721392     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: 10.1053/ajkd.2001.29261     Document Type: Article

References (37)

1. Diabetic nephropathy in type 1 (insulin-dependent) diabetes: An epidemiological study
2. Unchanged incidence of diabetic nephropathy in IDDM patients
3. Diabetic nephropathy
4. Progression of nephropathy in longterm diabetics with proteinuria and effect of initial antihypertensive treatment
5. A prospective study of glomerular filtration rate and arterial blood pressure in insulin-dependent diabetics with diabetic nephropathy
6. Monitoring glomerular function in diabetic nephropathy
7. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease: Probable benefits of increasing folic acid intakes
8. Prospective study of serum total homocysteine concentration and risk of stroke in middle-aged British men
9. Serum total homocysteine and coronary heart disease
10. Plasma homocysteine is related to albumin excretion rate in patients with diabetes mellitus: A new link between diabetic nephropathy and cardiovascular disease?
11. Hyperhomocyst(e)inemia and endothelial dysfunction in IDDM
12. Fibrinolysis and atherosclerosis
13. The localization of plasminogen activator inhibitor-1 in glomerular subepithelial deposits in membranous nephropathy
14. Aldosterone modulates plasminogen activator inhibitor-1 and glomerulosclerosis in vivo
15. Progression and potential regression of glomerulosclerosis
16. Lack of relationship between an insertion/deletion polymorphism in the angiotensin-I-converting enzyme gene and diabetic nephropathy and proliferative retinopathy in IDDM patients
17. Insertion/deletion polymorphism in the angiotensin-I-converting enzyme gene is associated with coronary heart disease in IDDM patients with diabetic nephropathy
18. Early aggressive antihypertensive treatment reduces rate of decline in kidney function in diabetic nephropathy
19. Microalbuminuria: An early marker of renal involvement in diabetes
20. Homocysteine and other thiols in plasma and urine: Automated determination and sample stability
21. Selection of routine method for determination of glomerular filtration rate in adult patients
22. Enzyme immunoassay: An improved determination of urinary albumin in diabetics with incipient nephropathy
23. Predictors of the progression of renal insufficienty in patients with insulin-dependent diabetes and overt diabetic nephropathy
24. Plasma homocysteine concentration predicts mortality in non-insulin-dependent diabetic patients with and without albuminuria
25. Homocysteine and atherothrombosis
26. Cigarette smoking and plasma total homocysteine levels in young adults with type 1 diabetes
27. Total homocysteine in patients with type 1 diabetes
28. Total homocysteine is associated with nephropathy in non-insulin-dependent diabetes mellitus
29. Hyperhomocysteinemia in end-stage renal disease: Prevalence, etiology, and potential relationship to arteriosclerotic outcomes
30. The role of angiotensin II and plasminogen activator inhibitor-1 in progressive glomerulosclerosis
31. Features of endothelial dysfunction in early diabetic nephropathy
32. Tissue-type plasminogen activator antigen and plasminogen aclivator inhibitor in diabetes mellitus
33. PAI-1 and factor VII activity are higher in IDDM patients with microalbuminuria
34. Plasminogen activator inhibitor-1 and apolipoprotein E gene polymorphisms and diabetic nephropathy
35. Modulation of plasminogen-activator inhibitor-1 in-vivo-a new mechanism for the anti-fibrotic effect of renin-angiotensin inhibition
36. Promotion, prediction, and prevention of progression in diabetic nephropathy
37. Progression of diabetic nephropathy